On December 28, 2023, the FDA Informed MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued. This Clinical Hold letter rejects the …
FOR IMMEDIATE RELEASE: December 13, 2023 MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from …
FOR IMMEDIATE RELEASE: December 4, 2023 Yesterday’s highly anticipated football game between the San Francisco 49ers and the Philadelphia Eagles brought additional excitement to the field thanks to 49ers’ …
MAPS’ proposed Study MJP2 study is a research study that is intended to add to the cannabis safety literature and contribute to a better understanding of the safety and effectiveness of real-world …
FOR IMMEDIATE RELEASE: November 11, 2023 In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical …
Many in the MAPS community are grieving the loss and suffering experienced by family, friends, colleagues, and countless others impacted by the Israel-Hamas war. At MAPS, we have been in deep dialogue …
PS2023: The Virtual Trip, produced by the Multidisciplinary Association for Psychedelic Studies (MAPS), has published an additional 40 session videos from Psychedelic Science 2023, showcasing a trove of …
FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
The Multidisciplinary Association for Psychedelic Studies (MAPS) has begun publishing a collection of content from the highly acclaimed Psychedelic Science 2023 conference. PS2023: The Virtual Trip brings …
On August 11, the FDA Division of Pulmonology, Allergy, and Critical Care (DPACC) sent MAPS additional guidance on the safety of smoking in naïve subjects in MJP2. The FDA’s correspondence was a …
On July 12, 2023, the FDA Division of Psychiatry sent MAPS the official minutes of our Type A meeting on June 15, 2023. The Type A meeting focused on the issues the FDA cited in its Clinical Hold on the …
MAPS and the Steven & Alexandra Cohen Foundation Partner to Support the Development of Psychedelic-Assisted Therapies FOR IMMEDIATE RELEASE: June 22, 2023 TheMultidisciplinary Association for Psychedelic …